EquitySectoral/ ThematicRegularGrowthVery High

ITI Pharma and Healthcare Fund

Q: What is the NAV of ITI Pharma and Healthcare Fund?

As of 01 Oct 2026, the NAV of ITI Pharma and Healthcare Fund is ₹17.63 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

Q: What returns has ITI Pharma and Healthcare Fund delivered?

ITI Pharma and Healthcare Fund has returned +10.44% over 1 year, +16.65% per year over 3 years and +12.29% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

Q: What is the expense ratio of ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund charges an expense ratio of 2.59% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

Q: What are the top holdings of ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund's largest holdings are Sun Pharmaceutical Industries Limited (12.6%), Divi's Laboratories Limited (9.2%), Apollo Hospitals Enterprise Limited (5.7%), Max Healthcare Institute Limited (4.8%) and Torrent Pharmaceuticals Limited (4.8%). Holdings are disclosed monthly and change over time.

Q: How risky is ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 14.2% and its worst peak-to-trough fall in our sample was -18.5%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

Q: What does the Sharpe ratio of 0.71 mean?

The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. ITI Pharma and Healthcare Fund's 0.71 means it has rewarded its volatility with excess return. Higher is better.

Q: What is the benchmark of ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund is benchmarked against the Nifty Healthcare Total Return Index. Its alpha and beta on this page are measured against that index.

Q: Who manages ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund is managed by Animesh Singh and Nilay Dalal at ITI.

Q: How is ITI Pharma and Healthcare Fund taxed?

ITI Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.

ITI Mutual Fund · Best Sectoral & Thematic Mutual Funds

NAV

₹17.63

-0.20% 1D

as of 01 Oct 2026

This is the Regular plan of ITI Pharma and Healthcare Fund — bought through a distributor, whose commission is paid out of its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.

Compare SIP calculator

Performance

+11.61%CAGR

52-week rangePrev NAV ₹17.66

Latest ₹17.63

Low ₹14.5079th percentile of its 52-week rangeHigh ₹18.45

Scorecard

★★★★☆4/5 vs 142 of 255 Sectoral/ Thematic peers

Performance 60%
Risk 15%
Cost 10%
Downside 15%

How this is computed

Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. The stars weight the same ground 60/15/10/15 (performance/risk/cost/downside) across every fund in the peer group. Ranked within Sectoral/ Thematic (same plan and option). 142 of the 255 Sectoral/ Thematic funds in this cohort carry the full record the stars need, so they are the ones ranked against.

PerformanceStrong

3Y CAGR +16.65% · ranks 30 of 142 Sectoral/ Thematic funds

RiskModerate

Volatility 14.2% vs 15.6% category avg

CostAverage

2.6% expense vs 2.5% category avg

ConsistencyHigh

100% of rolling 3Y windows were positive

Strengths & concerns

Generated from this fund's own numbers against its sub-category — each point names the figure behind it.

Strengths

Ahead of the Sectoral/ Thematic average on 1M/3M/6M/1Y — 1Y by 8.22pp
3-year return (+16.65%) beats the Sectoral/ Thematic average (+12.12%)
Stronger risk-adjusted returns — Sharpe 0.71 vs 0.34 Sectoral/ Thematic average
Consistent — positive in 100% of rolling 3-year windows

Concerns

No significant concerns identified.

Key Metrics

Annual fee charged by the fund, already deducted from NAV

2.59%

Category 2.46%▲0.13%

Portfolio-weighted harmonic mean P/E across the fund's equity holdings

47.33

Category —

Excess return per unit of total volatility (rf = 6.5%)

0.71

Category 0.34▲0.37

Scheme Info

Definitions

Plan

Regular · Growth

Period before units can be redeemed — 3 years for ELSS, none for most open-ended funds

None

If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL

Up to 0.50%

tiered — see the full terms

Statutory levy on every mutual-fund purchase since 1 Jul 2020 (SEBI / Govt of India) — the same for every scheme

0.005%

SIP Inv.

Allowed

Smallest recurring SIP instalment the scheme accepts

₹500

Smallest one-time (lumpsum) investment the scheme accepts

₹5,000

Nifty Healthcare Total Return Index

Nifty Healthcare TRI

Start of our NAV history for this plan. Direct plans begin 1 Jan 2013, so this is the plan's inception — not necessarily the scheme's original launch date.

11 Nov 2021

Period returns (<1Y, absolute — not annualized)

Definitions

Absolute return over the last 1 month (not annualized)

-3.15%

Absolute return over the last 3 months (not annualized)

+2.05%

Absolute return over the last 6 months (not annualized)

+19.10%

Absolute return since 1 Jan of this year (not annualized)

+12.33%

Annualized returns (≥1Y — CAGR)

Definitions

1-year point-to-point return, annualized (CAGR)

+10.44%

3-year annualized return (CAGR)

+16.65%

5-year annualized return (CAGR)

—

10-year annualized return (CAGR)

—

Annualized return (CAGR) since the first NAV we hold for this plan — the Inception date under Key metrics. AMFI's history starts in April 2006, so an older scheme is measured from there.

+12.29%

Advanced metrics — risk and benchmark ratios

Risk (trailing 3Y)

Definitions

Annualized standard deviation of daily returns

14.23%

Excess return per unit of total volatility (rf = 6.5%)

0.71

Excess return per unit of downside deviation — upside swings aren't penalized (rf = 6.5%)

0.99

Largest peak-to-trough decline over full history

-18.53%

Benchmark ratios (vs Nifty 500 TRI · 36 monthly returns)

Definitions

Jensen's alpha (annualized): return above what CAPM predicts for the fund's beta vs Nifty 500 TRI

7.28%

Sensitivity to Nifty 500 TRI moves; 1 = moves with the index

0.80

How much of the fund's movement Nifty 500 TRI explains

56.7%

Excess return per unit of beta (market risk)

12.84

Active return over the benchmark per unit of tracking error

0.61

Annualized std dev of fund-minus-benchmark returns

11.46%

Fund's share of benchmark gains in up months (100 = matches index)

110.3%

Fund's share of benchmark losses in down months (lower is better)

77.8%

Computed vs the Nifty 500 TRI over the last 36 complete months — the closest match to this fund's mandate. TRI means dividends reinvested, as they are in the fund's own NAV; ₹ means a US index converted at each day's USD/INR, since the fund is priced in rupees. Needs ~3 years of history; a low R² means the fund tracks the index loosely.

Fund vs category average (Sectoral/ Thematic)

Period	Fund	Category avg.	Diff
1M abs	-3.15%	-5.15%	+2.00%
3M abs	+2.05%	-2.36%	+4.41%
6M abs	+19.10%	+10.78%	+8.32%
1Y CAGR	+10.44%	+2.22%	+8.22%
3Y CAGR	+16.65%	+12.12%	+4.53%
5Y CAGR	—	+11.03%	—

Category average across peers in Sectoral/ Thematic (254 of 255 carry a figure for at least one period), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).

Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.

Category rank

Vs 255 peers in Sectoral/ Thematic

1Y return

+10.44%

Beats 79.8% · rank #47

3Y return

+16.65%

Beats 79.4% · rank #30

5Y return

—

Sharpe

0.71

Beats 81.6% · rank #27

Sortino

0.99

Beats 83% · rank #24

Backtest this fund

What a SIP or one-time investment would have grown to over this fund’s real NAV history.

Monthly investment (₹)

Period

Invested

₹3.60L

Current value

₹4.17L

Absolute

+15.92%

XIRR

+10.38%

Value vs. invested

ValueInvested

36 monthly installments of ₹10,000 into ITI Pharma and Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.

Calendar-year returns

What the fund actually returned in each year, not the smoothed average.

Year	Fund	Nifty 500 TRI	Diff
2026part	+12.33%	-7.18%	+19.51%
2025	-9.96%	+7.94%	-17.90%
2024	+41.25%	+16.43%	+24.82%
2023	+31.61%	+27.43%	+4.18%
2022	-8.68%	+4.34%	-13.02%
2021part	+2.63%	—	—

January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.

History points

1,205

Expense ratio

2.59%

AUM

₹233.89Cr

Portfolio turnover

47%

Exit load

If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL

Portfolio, AUM & scheme details shown from another plan of this scheme (same underlying portfolio).

P/E ratio

47.3

P/B ratio

8.7

Avg market cap

₹1,34,250Cr

P/E & P/B are portfolio-weighted harmonic means across 34 of 37 equity holdings (95% of the portfolio); loss-making companies are excluded.

Taxation

Taxed as equity

This is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.

Short-term (STCG)

20%

Held under 1 year

Flat, on the whole gain

Long-term (LTCG)

12.5%

Held 1 year or more

On gains above ₹1.25 L per financial year

Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.

Peer comparison · Sectoral/ Thematic

Compare all


ITI Pharma and Healthcare FundThis fund ITI · Regular · Growth	★★★★☆	+10.44%	+16.65%	—	—	2.59%	₹233.89Cr
Nippon India Taiwan Equity Fund Nippon India · Regular · Growth	★★★★☆	+118.60%	+60.45%	—	—	2.34%	₹1,110Cr
HDFC Defence Fund HDFC · Regular · Growth	★★★★☆	+21.45%	+34.62%	—	—	1.79%	₹9,371Cr
HDFC Pharma and Healthcare Fund HDFC · Regular · Growth	★★★★★	+25.19%	+28.72%	—	—	2.11%	₹2,282Cr
Franklin Asian Equity Fund Franklin Templeton · Regular · Growth	★★★☆☆	+32.21%	+22.88%	+8.49%	—	2.47%	₹720.84Cr
Aditya Birla Sun Life International Equity Fund Aditya Birla Sun Life · Regular · Growth	★★★★☆	+17.38%	+21.97%	+12.58%	—	2.54%	₹320.62Cr

Market-cap allocation · AMFI bands, Jul 2026

Equity holdings by company size — 100% of the equity sleeve priced.

Large cap37.5%
Mid cap42.6%
Small cap20.0%

Asset allocation

As on 31 Aug 2026 · AMC disclosure

Equity99.27%
Cash & Equivalents0.73%

which companies this fund invests in

As on 31 Aug 2026 · AMC disclosure

Sun Pharmaceutical Industries Limited

12.58%

Divi's Laboratories Limited

9.23%

Apollo Hospitals Enterprise Limited

5.72%

Max Healthcare Institute Limited

4.84%

Torrent Pharmaceuticals Limited

4.75%

Dr. Reddy's Laboratories Limited

4.31%

Cipla Limited

4.22%

Laurus Labs Limited

4.02%

Aurobindo Pharma Limited

3.97%

Mankind Pharma Limited

3.31%

Holds the same stocks as (by portfolio overlap, not by category)

Compare the top 3 →

Fund	Overlap	Rating	TER	3Y
Bandhan BSE Healthcare Index Fund Bandhan · Index Funds	74.5%	★★★★★	0.34%	—
DSP Nifty Healthcare Index Fund DSP · Index Funds	72.0%	★★★★★	0.40%	—
Mirae Asset Healthcare Fund Mirae Asset · Sectoral/ Thematic	66.4%	★★★★★	0.62%	+21.71%
SBI Healthcare Opportunities Fund SBI · Sectoral/ Thematic	65.8%	★★★★★	1.01%	+22.78%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Edelweiss · Index Funds	62.7%	★★★★★	0.55%	+18.52%
HDFC Pharma and Healthcare Fund HDFC · Sectoral/ Thematic	60.7%	★★★★★	1.03%	+30.26%
Nippon India Nifty Pharma ETF Nippon India · Other ETFs	60.4%	—	0.23%	+19.93%
ICICI Prudential Nifty Pharma Index Fund ICICI Prudential · Index Funds	60.4%	★★★★★	0.51%	+19.50%

Overlap is the share of each fund's equity book invested in the same stocks, by weight, across the Direct-plan universe — so a fund that is only part equity is labelled as such. ! marks a pair holding more in common than nine pairs in ten of its type, where that type has a measured distribution.

🚩Holdings under NSE surveillance (ASM)

1 holding — 1.59% of the portfolio — sit in stocks NSE currently lists under its Additional Surveillance Measure. ASM is an exchange response to unusual price or volume activity (higher margins, and trade-for-trade settlement at stage II), not a view on the company or on this fund.

Shilpa Medicare LimitedLong-term · Stage I1.59%

Source: NSE ASM list, matched to holdings by company name — a holding whose name differs from NSE's spelling may not be matched. BSE's separate list is not covered.

Worst falls, and the wait to get back

How far this fund has dropped from a high, and how long it took to reclaim it.

-18.5%13 Jan 2022 → 17 Jun 2022
Fell over 5 months, back to the old high on 06 Jul 2023 — 13 months under water after the low.
-17.6%02 Jan 2025 → 29 Jan 2026
Fell over 13 months, back to the old high on 03 Jul 2026 — 5 months under water after the low.
-6.3%23 Feb 2024 → 19 Mar 2024
Fell over 25 days, back to the old high on 09 Apr 2024 — 21 days under water after the low.

Measured on this fund’s own NAV history, peak to trough to the day it regained the peak. Falls shallower than 5% are left out. A recovery date is when the NAV got back, not when any particular investor did — that depends on when they bought.

Fund size over time

Quarterly average AUM · AMFI

₹233.89Cr

April - June 2026

+8%

since January - March 2026

−₹7.60Cr

est. net flow, last quarter

At or near its largest, ₹233.89Cr in April - June 2026. Size matters most where the mandate is narrow — a large small-cap or a very large flexi-cap book is harder to move without moving the price.

Net flow is an estimate: AMFI publishes a quarterly average AUM, not a closing balance, and it covers every plan and option of this scheme together, so it is a read on direction and rough size rather than a cash-flow statement.

AMC Profile

ITI Mutual Fund is run by ITI Asset Management, part of the Investment Trust of India group. It launched its first schemes in 2019 and runs a mix of equity, hybrid and debt funds.

Launched

13 May 2018

Total AUM

₹11,302Cr+4.4% QoQ

Avg AUM · April - June 2026

Website

itiamc.com

Fund Managers

ASAnimesh SinghManaging since 08 May 2026

Role

Fund Manager

Education

Post Graduate Diploma in Management. Bachelor of Honours - (Economics) CFA – USA Certification

Experience

Mr. Animesh Singh is an investment management professional with over 20 years of experience in portfolio management, equity research, and investment advisory services. Prior to Joinig ITI AMC, he served as Director – Investment & Portfolio Manager at Julius Baer Wealth Advisory, where he managed Alternative Investment Fund (AIF) portfolios and advised clients on investment strategies across asset classes. Prior to this, he held senior roles at Centrum Wealth and Nippon Life India Asset Management, managing equity advisory portfolios, PMS mandates, and institutional investment portfolios. He began his career in equity research and credit analysis, covering sectors such as telecom, media, FMCG, and automobiles.

NDNilay DalalManaging since 08 May 2026

Role

Equity Fund

Education

MBA (Finance)

Experience

Mr. Nilay Dalal joined ITI Asset Management Limited in April 2023 and has over 13 years of work experience in financial markets. Past Experience : December 2019 – April 2023 with Axis Asset Management Company as Equity Research Analyst. May 2011 – December 2019 with SBI Life Insurance as Equity Research Analyst

Funds managed (3)

All schemes Nilay Dalal runs →

Fund managers from the AMC's filed Scheme Summary — its most recent filing for this scheme. Benchmark and dealing terms from it and this scheme's SEBI-filed Scheme Information Document on AMFI. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.

Explore from here

Fund managers

Nilay Dalal

Top holdings

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Apollo Hospitals Enterprise Limited Max Healthcare Institute Limited Torrent Pharmaceuticals Limited Dr. Reddy's Laboratories Limited Cipla Limited Laurus Labs Limited Aurobindo Pharma Limited Mankind Pharma Limited Neuland Laboratories Limited Cohance Lifesciences Limited

ITI in the news

Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.

Run SIP calculator Add to compare

Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.

About Sectoral & Thematic funds

Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.

Frequently asked questions

What is the NAV of ITI Pharma and Healthcare Fund?

As of 01 Oct 2026, the NAV of ITI Pharma and Healthcare Fund is ₹17.63 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

What returns has ITI Pharma and Healthcare Fund delivered?

ITI Pharma and Healthcare Fund has returned +10.44% over 1 year, +16.65% per year over 3 years and +12.29% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

What is the expense ratio of ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund charges an expense ratio of 2.59% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

What are the top holdings of ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund's largest holdings are Sun Pharmaceutical Industries Limited (12.6%), Divi's Laboratories Limited (9.2%), Apollo Hospitals Enterprise Limited (5.7%), Max Healthcare Institute Limited (4.8%) and Torrent Pharmaceuticals Limited (4.8%). Holdings are disclosed monthly and change over time.

How risky is ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 14.2% and its worst peak-to-trough fall in our sample was -18.5%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

What does the Sharpe ratio of 0.71 mean?

The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. ITI Pharma and Healthcare Fund's 0.71 means it has rewarded its volatility with excess return. Higher is better.

What is the benchmark of ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund is benchmarked against the Nifty Healthcare Total Return Index. Its alpha and beta on this page are measured against that index.

Who manages ITI Pharma and Healthcare Fund?

ITI Pharma and Healthcare Fund is managed by Animesh Singh and Nilay Dalal at ITI.

How is ITI Pharma and Healthcare Fund taxed?

ITI Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.